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In this issue of Cell Stem Cell, Csaszar et al. (2012) develop a culture method that overcomes current
limitations in ex vivo hematopoietic stem/progenitor cell expansion by continuously diluting inhibitory
signaling factors and maintaining stem cell density. This approach enhances the generation of precursors
with potential therapeutic utility.An area of burgeoning interest in stem cell
biology has been the development of
methods for the ex vivo generation of
increased numbers of stem cells and their
specific derivatives for therapeutic appli-
cation. This is particularly relevant in
patients undergoing myeloablative cord
blood transplant (CBT), where delayed
myeloid engraftment resulting in a higher
incidence of early-transplant-related mor-
tality is a known risk factor that is asso-
ciated with the low CD34+ cell doses
provided in a single or double cord blood
(CB) graft (Brunstein et al., 2010). Thus,
with the goal of enhancing the time to
myeloid recovery and sustained donor
engraftment, extensive recent efforts
have been aimed at expanding the avail-
able numbers of hematopoietic stem/
progenitor cells (HSPCs) derived from
individual CB units. The ultimate goal of
this work would be the generation of
short-term repopulating cells that meet
an as of yet undefined threshold to abolish
posttransplant neutropenia while pro-
viding long-term repopulating cells for
sustained donor hematopoiesis.
Past studies have used cytokines to
expand hematopoietic repopulating cells
but have led to limited expansion or main-
tenance of precursors and have not
proven clinically effective. More recent
novel approaches, however, are showing
greater promise toward generation of
therapeutically useful numbers of CB-
derived progenitor cells by ex vivo expan-
sion (for review, see Dahlberg et al., 2011).
Other investigators have focused on
enhancing the ability of the lower numbers
of stem cells available in a CB unit to
home to the stem cell niche, using PGE2
inhibitors or enhancers of CXCR4 expres-
sion to improve engraftment (Hoggatt
et al., 2009; Campbell and Broxmeyer,2008). While this approach may enhance
the likelihood of sustained donor en-
graftment, it may be limited in its ability
to abrogate early posttransplant neutro-
penia. In the clinic, successful engraft-
ment of CB progenitor cells generated
in ex vivo cultures with Notch ligand or
MSC cocultures with cytokines has been
demonstrated to enhance posttransplant
neutrophil recovery (Delaney et al., 2010;
Yang et al., 2010), thereby providing proof
of principle that such HSPC enrichment
methods can prove therapeutically useful.
However, none of these approaches
promote the sustained generation of pro-
genitor cells in culture over time, thus
limiting the total number of cells gener-
ated. These limitations in current method-
ological approaches for progenitor/stem
cell expansion present an important con-
sideration with potential impact on clinical
efficacy.
In this issue of Cell Stem Cell, Csaszar
et al. (2012) overcome the decline in
progenitor cell expansion over time with
the development of a ‘‘biologically based’’
culture system that addresses the com-
plex and changing properties of cultured
cells. The authors first addressed whether
limitations of HSPC expansion using
conventional culture methods with peri-
odic media changes result from negative
feedback effects due to inhibitory factors
elaborated by mature cells developing
within the cultures. They found accumula-
tion of a number of potentially inhibitory
factors between media changes, and
validated the functional significance of
a portion of these factors by adding
back TGF-b1, MIP-1a, and IP-10, or using
a small molecule inhibitor of TGF-b1. In
a past study, effects of negative feedback
and increasing cell density have been
overcome by periodically removingCell Stem Cell 10mature myeloid progeny to achieve
extensive CD34+ cell expansion (Piaci-
bello et al., 1997). Unfortunately, this
approach resulted in a limited 6-fold
expansion of repopulating cells, and is
too complex for clinical implementation
given the requirement for extensive
repeated culture manipulation and ex-
pected cell losses. In contrast, Csaszar
et al. (2012) provide a clinically feasible
approach for preventing significant accu-
mulation of inhibitory factors and main-
taining cell densities using an automated
‘‘fed-batch’’ culture system in which
additional media is added at frequent,
essentially continuous, intervals to dilute
inhibitory factors that accumulate in the
media and to maintain stem cell density.
Given the complexity of cultures with
respect to the number and fluctuation of
inhibitory factors, the authors reasoned
that targeted molecular approaches
would prove insufficient. They used
computational approaches to design an
optimal ‘‘feeding’’ schedule and, using
this approach in an automated and
tunable closed system bioreactor, vali-
dated significant enhancement of pre-
cursor cell generation. Specifically, the
authors report a significant increase in
the absolute numbers of CD34+ cells
and an approximate 11-fold increase in
hematopoietic repopulating cells in trans-
plantation studies in immune-deficient
mice, thus showing promise for clinical
application. Integration of the known
HSC growth reagent, SR1 (Boitano et al.,
2010), was shown to further enhance
precursor expansion under fed-batch
conditions, emphasizing the utility of this
bioengineering method in ameliorating
negative feedback signaling and en-
hancing ex vivo expansion. On the other
hand, the ability of HoxB4 to enhance, February 3, 2012 ª2012 Elsevier Inc. 113
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reduced in their fed-batch system,
consistent with the idea that HoxB4 func-
tions in a non-stem-cell autonomous
manner to promote stem/progenitor
growth (Kirouac et al., 2010). Further
studies integrating novel methods for
expansion in this bioengineered system
are clearly warranted, with the hope of
achieving expansion of HSPCs sufficient
to meet clinical needs.
However, challenges remain if this
technology is to have clinical impact. First,
the reproducible generation of sufficient
numbers of precursor cells to achieve
sufficiently rapid neutrophil engraftment
to markedly reduce or eliminate the
clinical consequences of neutropenia is
necessary. Second, ex-vivo-expanded
HSPCs in the CBT setting have not been
evaluated as the sole source of long-
term repopulating cells, and thus the
issue of whether such cells have been
generated remains unanswered. Although
transplantation studies in immune-
deficient mice suggest the possibility of
long-term repopulating cell maintenance
or expansion, further validation will need
to come from nonhuman primate studies
or possibly from current trials in which
T cells obtained prior to expansion are
added back to protect the expanded
cells from rejection by T cells in an ac-
companying nonexpanded CB unit.
Lastly, there is the need to develop cost
effective approaches. Although the ap-
proach used by Csaszar et al. (2012)
involves tightly regulated feeding of
medium that should decrease media114 Cell Stem Cell 10, February 3, 2012 ª201usage, further improvements in reducing
usage of this costly component will
be required. Future approaches might
include reutilizing medium, removing
deleterious factors, and replenishing re-
quired ones, possibly through processes
akin to dialysis. Alternatively, it is still
conceivable that inhibitory small mole-
cules or antibodies will be developed
and a combination will be utilized to
prevent negative feedback effects, the
potential success of which is suggested
by results using aTGF-b inhibitor. An addi-
tional aspect of cost concerns relates to
the need for real-time ex vivo expansion
of costly HLA-matchedunits as the source
of stem cells. These costly aspects may
be overcome if methods such as the fed-
batch approach discussed here enable
the generation of sufficient numbers of
stem/progenitor cells to overcome rapid
graft rejection. Cryopreservation of such
cells could provide a readily available
off-the-shelf therapy and extend the use
of expanded HSPCs to myelosuppressed
patients, not only as a result of posttrans-
plant conditioning but also in chemo-
therapy-induced severe neutropenia or
other acquired causes of neutropenia.
We anticipate that the methodology
presented by Csaszar and colleagues
will provide a platform on which current
and future methods for promoting stem
cell self-renewal can be optimized. We
also anticipate increasing interest in bio-
logically based bioengineering systems
that will prevent negative feedback inhibi-
tion of HSC expansion in a cost effective
manner, thereby promoting the sustained2 Elsevier Inc.generation of progenitor cells over time.
Thus, the approach developed by Csas-
zar and colleagues could in the future
ultimately lead to widespread therapeutic
use of engineered stem cells and their
various progeny.REFERENCES
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